Technology

Zacharon's unique glycobiology expertise has enabled the development of an entirely new class of human therapeutics targeting the biosynthesis of glycans, the carbohydrate portions of glycoproteins, proteoglycans, and glycolipids. Zacharon scientists overcame historical challenges by integrating cell-based high-throughput screening technologies and highly sensitive glycan structural analysis tools, thus unlocking the potential of small molecule glycan-targeted drugs.